Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06910956 · ClinicalTrials.gov registry record · NA

Deep Learning Using Chest X-Rays to Identify High Risk Patients for Lung Cancer Screening CT

A NA study of Lung Cancer and Early Cancer Detection, sponsored by Massachusetts General Hospital.

Recruiting
Registry status
NA
Development phase
1,500
Enrollment target
1
Study location

NCT06910956: Recruiting NA study of Lung Cancer and Early Cancer Detection, sponsored by Massachusetts General Hospital.

NCT06910956 is a NA study of Lung Cancer and Early Cancer Detection that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 1,500 participants, above the 932-participant average among 409 other Lung Cancer trials with a reported enrollment target (61% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT06910956, a NA study of Lung Cancer and Early Cancer Detection, is actively recruiting participants, sponsored by Massachusetts General Hospital.

RECRUITING
Registry status
NA
Development phase
1,500 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical trial is to evaluate whether an AI tool that alerts providers to patients at high 6-year risk of lung cancer based on their chest x-ray images will improve lung cancer screening CT participation. The main question it aims to answer is: Does the AI tool improve lung cancer screening CT participation at 6 months after the baseline outpatient visit The intervention is an alert to the provider to discuss lung cancer screening CT eligibility, for patients considered at high risk of lung cancer based on CXR-LC AI tool. If there is a comparison group: Researchers will compare intervention and non-intervention arms to determine if lung cancer screen CT participation increases.

Primary Outcome

To assess impact on lung cancer screening CT participation (defined as completing lung cancer screening CT) in the 6 months after the baseline visit.

Interventions

  • OTHER CXR-LC

Study Locations (1)

Massachusetts

  • Massachusetts General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 1,500 participants
Start Date 2025-05-20
Est. Completion 2027-07-01
Phase NA
Massachusetts General Hospital

2,032 total trials

What NCT06910956 shows while recruiting

NCT06910956 is an interventional study that assigns participants to a tested intervention. Its 1,500 participants enrollment target places it among the larger protocols in the corpus, above the 932-participant average among 409 other Lung Cancer trials with a reported enrollment target (61% higher).

The record links to 4 conditions, with Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which CXR-LC is the first listed.

NCT06910956 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06910956 about?

NCT06910956 is a clinical study titled "Deep Learning Using Chest X-Rays to Identify High Risk Patients for Lung Cancer Screening CT". The goal of this clinical trial is to evaluate whether an AI tool that alerts providers to patients at high 6-year risk of lung cancer based on their chest x-ray images will improve lung cancer screening CT participation. The main question it aims to answer is: Does the AI tool improve lung cancer s...

What is the current status of trial NCT06910956?

This trial is currently recruiting. It is a NA study. The enrollment target is 1,500 participants. The study started on 2025-05-20. Estimated completion is 2027-07-01.

What conditions does trial NCT06910956 study?

This clinical trial studies the following conditions: Lung Cancer, Early Cancer Detection, Health Screening, Deep Learning.

What interventions are being tested in trial NCT06910956?

The interventions under investigation include: CXR-LC (OTHER).

Who is sponsoring clinical trial NCT06910956?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06910956 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06910956's enrollment target sits among peer trials

1,500 36th of 409 higher than 374 of 409 other Lung Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00178724 · 1,500 participants

    Spinal Cord Injury Registry - North American Clinical Trials Network

  • NCT00951366 · 1,500 participants

    Preterm Lung Patient Registry

  • NCT01050504 · 1,500 participants

    Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer

  • NCT02071134 · 1,500 participants

    Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06910956, the US trial registry maintained by the National Library of Medicine. NCT06910956 (large enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.